Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Neurocrine (NBIX) and Orchard Therapeutics (ORTX)
TipRanksOct 10, 2023 10:10
Stifel Downgrades Orchard Therapeutics to Hold, Announces $16 Price Target
BenzingaOct 5, 2023 22:36
Orchard Therapeutics Analyst Ratings
BenzingaAug 9, 2023 21:59
Cantor Fitzgerald Reiterates Overweight on Orchard Therapeutics, Maintains $15 Price Target
BenzingaJun 27, 2023 20:18
Oppenheimer Adjusts Orchard Therapeutics Price Target to $34 From $37, Maintains Outperform Rating
MT NewswiresJun 13, 2023 20:54
Oppenheimer Maintains Outperform on Orchard Therapeutics, Lowers Price Target to $34
BenzingaJun 13, 2023 20:03
Cantor Fitzgerald Maintains Overweight on Orchard Therapeutics, Raises Price Target to $15
BenzingaMar 28, 2023 19:05
Oppenheimer Adjusts Orchard Therapeutics Price Target to $37 From $5, Maintains Outperform Rating
MT NewswiresMar 13, 2023 21:17
No Data
No Data